ArticleGels (Basel, Switzerland)2025
Formulation of PVA Hydrogel Patch as a Drug Delivery System of Albumin Nanoparticles Loaded with Curcumin.
Article in Gels (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Crosslinking-Dependent Design of Hyaluronic Acid Matrices for Enhanced Bioadhesion and Cellular Response.Pharmaceutics · 2026Article
- Photothermal-Responsive Polyvinyl Alcohol/Gelatin/Graphene Oxide Hydrogels Loaded with Quercetin for NIR-Triggered Controlled Drug Delivery.Gels (Basel, Switzerland) · 2026Article
- Curcumin in colorectal cancer: preventive strategies and therapeutic mechanisms.Cancer chemotherapy and pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Curcumin is a widely researched natural molecule due to its abundance of pharmacological effects, such as antioxidant, antitumor, anti-inflammatory, etc. The main limitation of curcumin, however, is its low aqueous solubility, which worsens its biopharmaceutical characteristics. The aim of this study was to encapsulate curcumin in albumin nanoparticles and to subsequently incorporate them into a polyvinyl alcohol patch, resulting in a new drug formulation for skin application. The nanoparticles were characterized by a small mean diameter of approximately 162 nm, a narrow size distribution, and a negative zeta potential. TEM confirmed the small size of the nanoparticles. The ratio between the drug and albumin was optimized, achieving approximately 88% encapsulation efficiency. Protein-ligand docking, utilizing CB-Dock, indicated a strong interaction between curcumin and albumin. The binding between the molecules was proved via diffuse-reflectance UV-vis and XRD analyses. The encapsulated curcumin showed a significantly potentiated scavenging activity against ABTS and DPPH radicals in comparison with the pure drug, as well as a protective effect in H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.